期刊
GENE THERAPY
卷 10, 期 9, 页码 803-809出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3301950
关键词
Wiskott-Aldrich; immunodeficiency; oncoretroviral vector
类别
资金
- NCI NIH HHS [P30 CA21765] Funding Source: Medline
- NHLBI NIH HHS [P01 HL 53749] Funding Source: Medline
- NIAID NIH HHS [R21 AI079757] Funding Source: Medline
T-cell dysfunction is thought to be central to the immunodeficiency state seen in patients with the Wiskott-Aldrich syndrome (WAS). Aspects of the WAS phenotype have been corrected in other cell types on introduction of the normal WAS protein (WASP), but the potential for correction of the T-cell defects has not been evaluated. Here we demonstrate that an oncoretroviral vector encoding WASP and green fluorescent protein (GFP), and pseudotyped with the RD114 envelope protein, efficiently transduces primary human T cells derived from WAS patients. Transcription initiated at the oncoretroviral long terminal repeat (LTR) results in levels of WASP that, while lower than those seen in normal control T cells, resulted in correction of the deficient proliferative response to T-cell receptor (TCR) stimulation characteristic of WAS. IL2 secretion after TCR stimulation was partially corrected. Control primary T cells transduced with the same vector responded normally to TCR stimulation, and showed no increase in WASP expression. The demonstration that correction of T cell defects can be achieved by gene transfer supports continued efforts to develop gene therapy for WAS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据